Short answer: in animal studies, BPC-157 has a strikingly clean safety record. Across mice, rats, rabbits and dogs, researchers have not reported serious toxicity. In humans, the honest answer is that almost nobody has looked. As of October 2026 there is no published randomized controlled trial, and the human safety data adds up to a handful of people. So when someone tells you BPC-157 has “no side effects,” what they really mean is that no one has measured them yet. This guide covers what is known, what is not, and the risk that has nothing to do with the molecule itself.
Type “bpc 157” into Google and watch what it suggests. The very first suggestion after the name itself is “bpc 157 side effects.” Before “benefits,” before “peptide,” before anything else. That tells you something: people are curious about BPC-157, and they are nervous about it. Both reactions are reasonable. Let’s look at why.
Why everyone is asking
BPC-157 sits in an unusual spot. It has been studied for more than 30 years, mostly by one research group in Zagreb, Croatia, and a large share of that literature reports positive effects on tissue repair in animals. At the same time, it has never gone through the clinical trials that turn a compound into a medicine. That gap between a lot of animal data and almost no human data is exactly where the question “is it safe?” lives.
Here is how the evidence breaks down:
| Type of evidence | How much exists | What it can tell you |
|---|---|---|
| Animal studies | Hundreds of papers | Toxicity at high doses, organ effects, mechanisms |
| Formal preclinical toxicology | At least one dedicated study (2020) | Whether standard safety tests flag problems |
| Human case series and pilots | A few, with 2 to 16 people | Whether anything obvious goes wrong in the short term |
| Randomized controlled trials | None published | Real side-effect rates vs placebo |
| Long-term human data | None | Anything that takes months or years to appear |
What animal studies show
This is the strongest part of the case. A 2020 preclinical safety evaluation published in Regulatory Toxicology and Pharmacology tested BPC-157 using the kind of battery regulators expect before human trials. It reported that the peptide was well tolerated and did not produce serious toxic effects in mice, rats, rabbits or dogs.
A follow-up pharmacokinetics study in 2022 (Frontiers in Pharmacology) found that BPC-157 is cleared very quickly in rats and dogs, with a half-life under 30 minutes. It is broken down into smaller peptide fragments and amino acids. Fast clearance is generally reassuring from a toxicity standpoint, although it says nothing about effects that might come from repeated exposure over months.
A 2025 systematic review in HSS Journal (Hospital for Special Surgery) screened 544 articles and included 36 studies on musculoskeletal research. It found no adverse effects reported across several organ systems in preclinical work. It also noted that every included study was low-tier evidence (level IV or V).
The catch: “No toxicity in animals” is an important first filter. It is not the same as “safe in humans.” Many compounds that looked clean in rodents ran into problems in people. That is the reason human trials exist.
What human data exists (all of it)
This section is short because the evidence is short. Here is everything we could find that has been published or registered:
- Knee pain case series (2021). A retrospective review in Alternative Therapies in Health and Medicine followed up 16 people with knee pain; 14 reported relief. No control group, no blinding, no validated measurement tools, and the authors describe it as preliminary.
- Intravenous safety pilot (2025). Lee and Burgess reported a pilot in two healthy adults, published in the same journal. No adverse events were reported. Two people is a feasibility check, not a safety study.
- Ulcerative colitis program (Croatia, PL-14736). An earlier development program under this code reportedly reached phase 2, but full trial data was never published in a standalone peer-reviewed paper.
- Registered trials. A 2015 phase 1 trial (NCT02637284) was registered and apparently cancelled without results. A randomized, placebo-controlled pilot at the University of Arkansas for Medical Sciences (NCT07803250) on rotator-cuff surgery recovery was registered in September 2026 and is not expected to start until 2027.
Add those up and you get fewer than 20 people with any kind of documented outcome, none of them in a controlled trial. When the US FDA’s own staff reviewed BPC-157 in July 2026, they described “a general lack of quality data” on safety and effectiveness.
Anxiety, insomnia, nausea: the reported effects
Google’s suggestions show exactly what people worry about: can BPC-157 cause anxiety, insomnia, nausea, diarrhea, constipation, weight gain? These questions come from forum reports, not from studies. That matters, so here is how to read them.
| What people search | Is it in the published research? | How to read it |
|---|---|---|
| Anxiety, mood changes | No controlled human data. Animal work shows BPC-157 interacts with dopamine and serotonin systems. | Plausible enough to take seriously; impossible to confirm or rule out. |
| Insomnia | Not described in the literature. | Anecdotal. No control group, so it could be the compound, the context or coincidence. |
| Nausea, diarrhea, constipation | Not described in the literature. Animal studies mostly report protective gut effects. | Anecdotal. Contamination or wrong product are realistic explanations. |
| Weight gain | No. | No known mechanism. Most likely unrelated. |
| Dizziness, low blood pressure | Animal studies report effects on the nitric oxide system, which regulates blood vessels. | A reasonable theoretical concern; no human measurement. |
The pattern is the same throughout: no study has measured these effects in humans, so no one can tell you how often they happen. The only way to know is a placebo-controlled trial, and that has not been done.
The theoretical concerns researchers actually raise
1. Angiogenesis and cancer
One of BPC-157’s best-studied actions is promoting angiogenesis, the growth of new blood vessels, partly through the VEGFR2 pathway. That is part of why it is studied for wound and tendon repair. It is also why researchers raise a theoretical question about tumours, which need new blood vessels to grow. No study has shown BPC-157 causes cancer, and some animal studies report anti-tumour effects. But the question has not been tested in humans. We covered this in depth here: Does BPC-157 cause cancer? What the evidence actually says.
2. One research group
Most of the BPC-157 literature comes from Predrag Sikirić’s group at the University of Zagreb. That does not make it wrong. It does mean independent replication is thinner than the paper count suggests, and that “hundreds of studies” overstates how many independent teams have looked.
3. Long-term exposure
Animal studies are mostly short. Nothing tells us what happens with exposure over months or years.
The risk that is not about BPC-157
Here is the part most articles skip. Even if BPC-157 the molecule turns out to be very safe, that tells you nothing about a vial bought online. When Health Canada issued its April 2026 public advisory on unauthorized peptides, which named BPC-157 among others, the risks it listed were mostly about the product, not the compound:
- the wrong amount of active ingredient, or none at all;
- unlisted ingredients or contaminants;
- mislabelling, or improper manufacturing and storage;
- infections and allergic reactions.
For a peptide that is cheap to make and sold as a white powder, this is the risk that can actually be measured today. And in April 2026, someone measured it. Researchers Christopher Mendias and Tariq Awan analysed 6,441 samples of peptides sold directly to consumers, across 14 compounds, using independent lab data:
| Finding (all 14 peptides) | Result |
|---|---|
| Failed a basic quality standard (90–110% of label amount and ≥98% purity) | 41.6% |
| Failed a pharmaceutical-style standard (95–105% and ≥99.5%) | 71.1% |
| Measurable endotoxin (bacterial toxin), of 243 samples tested | 15% |
| BPC-157 samples that did not contain BPC-157 at all | 3.5% |
Two details stand out. BPC-157 was one of the peptides with the widest variation in how much was actually in the vial. And purity did not predict endotoxin: a vial can test 99% pure and still carry bacterial toxins, which is why a purity number alone does not settle the question. The study is a preprint and has not yet been peer-reviewed, but its scale is far beyond anything published before.
None of this shows up in the animal toxicology, because those studies used research-grade material made in controlled conditions.
This is why, for any laboratory work, the quality documentation is not a formality:
- Mass spectrometry identity confirming the molecular weight of about 1,419 Da.
- HPLC purity, ideally 98% or higher.
- A COA matched to the lot number on the vial, from a named lab.
- Proper storage from the moment it is made. See how to store peptides.
Our guide on how to read a peptide COA shows what to check line by line. TrueLabs BPC-157 lot results are in the COA library.
FDA, Health Canada and WADA: where BPC-157 stands
| US FDA | Not approved. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6 (1 abstention) to recommend adding BPC-157 to the list of substances pharmacies may compound. The vote is non-binding, and FDA staff had recommended against it. No rule has been finalized. |
|---|---|
| Health Canada | Not approved. Named in Health Canada’s April 2026 advisory on unauthorized peptides. Health Canada states that “research use only” labelling does not exempt a product from drug regulations. |
| WADA (sport) | Prohibited at all times under category S0, non-approved substances. Athletes subject to testing should treat it as banned. |
The split FDA vote captures the situation well. Committee members who voted yes generally saw the risks as low. Those who voted no worried that listing it would suggest BPC-157 meets the standard of an approved drug, which it does not.
Bottom line: BPC-157 has an encouraging animal safety record and almost no human safety record. The side effects people search for are unproven in both directions. The most concrete, measurable risk today is product quality. If you are dealing with an injury or pain yourself, a doctor or physiotherapist can offer treatments with real evidence behind them.
See TrueLabs BPC-157 and its COA →
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
What are the side effects of BPC-157?
No controlled human trial has measured BPC-157 side effects, so there is no reliable list. Animal studies, including a 2020 preclinical safety evaluation, reported no serious toxicity in mice, rats, rabbits or dogs. Effects reported online, such as nausea or insomnia, are anecdotal.
Is BPC-157 safe?
Its animal safety profile is favourable, but human safety has not been established. As of October 2026 there is no published randomized controlled trial, and the documented human data covers fewer than 20 people.
Can BPC-157 cause anxiety?
There is no controlled human data. Animal research shows BPC-157 interacts with dopamine and serotonin systems, so mood effects are plausible, but they have not been measured.
Does BPC-157 cause cancer?
No study has shown that it does. Because BPC-157 promotes blood-vessel growth in animal models, researchers raise a theoretical concern, but it has not been tested in humans.
Is BPC-157 FDA approved?
No. An FDA advisory committee voted 8–6 in July 2026 to recommend allowing pharmacy compounding, but the vote is non-binding and is not a drug approval.
Is BPC-157 banned in sport?
Yes. WADA lists BPC-157 under S0, non-approved substances, prohibited at all times.
Related reading
- How long does BPC-157 take to work?
- TB-500 side effects: what the human trials show
- Does BPC-157 cause cancer? What the evidence actually says
- BPC-157 vs TB-500: roads vs trucks
- Buy BPC-157 in Canada: price, purity and research
References
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. DOI
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022;13:1026182. PubMed
- Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PubMed
- Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13. PubMed
- Lee E, Burgess K. Intravenous BPC-157 safety pilot in two healthy adults. Altern Ther Health Med. 2025. PubMed
- Mendias CL, Awan TM. Evaluation of research grade peptides marketed directly to consumers reveals extensive variability in purity and measured abundance. Preprints.org. April 2026 (not peer-reviewed). Preprint
- Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you. Public advisory, April 9, 2026. Health Canada
- ABC News. FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list. July 23, 2026. ABC News
- ClinicalTrials.gov. NCT07803250 and NCT02637284. ClinicalTrials.gov
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use, and nothing in this article is medical advice. If you have an injury or chronic pain, please talk to a doctor or physiotherapist.